Want to see HK:6699 full AI Analyst Report?
Top Page
Angelalign Technology Inc.
(6699)
Select Model
Select Model
Rating:69Neutral
Price Target:
HK$103.00
â–²(14.13% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by strong financial stability and improved recent cash generation, which help limit financial risk. Technicals are supportive due to strong trend momentum, but the overbought RSI raises near-term pullback risk. The main drag is valuation, with a high P/E and low yield implying the stock is priced for strong execution and improved profitability consistency.
Positive Factors
Conservative balance sheet
Very low leverage and steady asset/equity growth provide durable financial flexibility, lowering solvency risk and enabling the company to fund capex, R&D or absorb demand shocks without forcing dilutive external financing. That stability supports multi-month operational execution and strategic optionality.
Negative Factors
Margin volatility
Meaningful margin compression and profit volatility reduce earnings predictability and weaken operating leverage. If cost or pricing pressures persist, it could limit the company's ability to convert sales into sustainable profits, requiring consistent execution to restore prior margin levels.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and steady asset/equity growth provide durable financial flexibility, lowering solvency risk and enabling the company to fund capex, R&D or absorb demand shocks without forcing dilutive external financing. That stability supports multi-month operational execution and strategic optionality.
Read all positive factors
Angelalign Technology Inc. (6699) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$16.63B
Dividend Yield0.5%
Average Volume (3M)814.93K
Price to Earnings (P/E)68.7
Beta (1Y)0.88
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees4,312
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.18
Shares Outstanding171,676,640
10 Day Avg. Volume786,597
30 Day Avg. Volume814,927
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)2.59
Price to Sales (P/S)3.49
P/FCF Ratio17.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$101.29Price Target Upside12.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.2
Revenue Forecast (FY)HK$482.87M
Angelalign Technology Inc. Business Overview & Revenue Model
Company Description
Angelalign Technology Inc. functions as an investment holding enterprise primarily dedicated to the innovation, production, and distribution of clear aligner solutions for orthodontic treatment throughout China. Their key offerings, Angel Aligner ...
How the Company Makes Money
Angelalign primarily makes money by selling orthodontic products and solutions used in clear aligner treatments. Its core revenue stream is generated from supplying clear aligner systems to dental/orthodontic clinics and hospitals for patient trea...
Angelalign Technology Inc. Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
86
Very Positive
Cash Flow
71
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.59B | 1.96B | 1.48B | 1.27B | 1.27B |
| Gross Profit | 1.60B | 1.23B | 920.71M | 785.69M | 826.65M |
| EBITDA | 293.27M | 77.34M | 154.39M | 318.65M | 372.47M |
| Net Income | 199.13M | 88.42M | 53.48M | 213.78M | 285.85M |
Balance Sheet | |||||
| Total Assets | 5.34B | 4.95B | 4.76B | 4.49B | 4.14B |
| Cash, Cash Equivalents and Short-Term Investments | 3.00B | 436.83M | 3.44B | 3.65B | 3.63B |
| Total Debt | 114.00M | 14.48M | 65.28M | 28.20M | 30.29M |
| Total Liabilities | 1.82B | 1.44B | 1.35B | 884.01M | 826.11M |
| Stockholders Equity | 3.49B | 3.46B | 3.34B | 3.61B | 3.32B |
Cash Flow | |||||
| Free Cash Flow | 523.39M | -76.78M | 51.28M | 51.48M | 241.95M |
| Operating Cash Flow | 712.07M | 229.79M | 165.87M | 146.87M | 441.71M |
| Investing Cash Flow | -1.26B | -138.82M | -981.71M | -159.77M | -182.05M |
| Financing Cash Flow | -175.45M | -28.46M | -187.06M | -193.61M | 2.52B |
Angelalign Technology Inc. Technical Analysis
Positive
90.25
Price Trends
85.17
Positive
80.40
Positive
72.11
Positive
Market Momentum
2.77
Negative
59.19
Neutral
76.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6699, the sentiment is Positive. The current price of 90.25 is below the 20-day moving average (MA) of 92.65, above the 50-day MA of 85.17, and above the 200-day MA of 72.11, indicating a bullish trend. The MACD of 2.77 indicates Negative momentum. The RSI at 59.19 is Neutral, neither overbought nor oversold. The STOCH value of 76.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6699.
Angelalign Technology Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
88 Outperform | HK$7.26B | 10.60 | 20.11% | 3.75% | 12.50% | 44.44% | |
69 Neutral | HK$16.63B | 68.75 | 5.84% | 0.50% | ― | ― | |
67 Neutral | HK$14.61B | 9.27 | 5.64% | 5.38% | 7.47% | -26.89% | |
67 Neutral | HK$1.39B | 28.88 | 1.10% | 6.63% | -1.64% | -68.67% | |
61 Neutral | HK$6.98B | 23.93 | 9.64% | 0.79% | 34.94% | 12.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6699
Angelalign Technology Inc.
94.80
28.49
42.95%
HK:1066
Shandong Weigao Group Medical Polymer Co
3.25
-2.22
-40.61%
HK:1358
PW Medtech Group Ltd.
0.97
-0.48
-33.36%
HK:3600
Modern Dental Group Limited
7.74
2.37
44.07%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
33.00
0.40
1.22%
Angelalign Technology Inc. Corporate Events
Angelalign Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Aug 3, 2026
Angelalign Technology Inc. has scheduled a board meeting for August 31, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider the payment o...
Angelalign forecasts sharp profit and revenue gains on aligner demand
Jul 31, 2026
Angelalign Technology Inc. expects a strong interim performance for the six months ended June 30, 2026, with clear aligner case volume rising about 40% to roughly 316,600 and revenue climbing over 40% to around USD229–231 million, while net ...
Angelalign grants 780,258 RSUs to key staff under post-IPO scheme
Jul 24, 2026
Angelalign Technology Inc. has granted 780,258 restricted share units to 255 employees under its post-IPO RSU scheme, with the awards representing an equivalent number of ordinary shares and including one member of senior management. The company s...
Angelalign Wins Shareholder Backing for New Clear Aligner Framework and Incentive Scheme Overhaul
Jul 23, 2026
Angelalign Technology Inc. secured shareholder approval at its extraordinary general meeting for a 2027–2029 Clear Aligners Purchase and Sales Framework Agreement, with all relevant ordinary resolutions passed by substantial majorities. Shar...
Angelalign Calls EGM to Overhaul Incentive Schemes and Clear Aligner Deal
Jul 2, 2026
Angelalign Technology Inc. has called an extraordinary general meeting in Shanghai on July 23, 2026, asking shareholders to approve continuing connected transactions under a new 2027–2029 clear aligners purchase and sales framework agreement...
Angelalign shifts from options to RSUs, expanding long-term incentive capacity
Jun 29, 2026
Angelalign Technology Inc. plans to terminate its post-IPO share option scheme, arguing that using restricted share units as the primary long-term incentive tool better matches its current needs while preserving all existing rights for grantees un...
Angelalign renews major connected sales and supply deals for 2027-2029
Jun 25, 2026
Angelalign Technology Inc. has renewed and extended its commercial relationship with CC Dental, a company controlled by its controlling shareholder CareCapital Group, through a new 2027-2029 Clear Aligners Purchase and Sales Framework Agreement. T...
Angelalign grants performance-linked share options to senior manager
Jun 25, 2026
Angelalign Technology has granted 55,964 share options to a senior management employee under its post-IPO share option scheme, exercisable at HK$68.12 per share over a ten-year period. The options will vest in four tranches between 2026 and 2029, ...
Angelalign Shareholders Approve All AGM Resolutions and Special Dividend
May 19, 2026
Angelalign Technology Inc. reported that all resolutions tabled at its 19 May 2026 annual general meeting were passed by shareholders, including approval of the 2025 audited financial statements and broad mandates for the board to issue and repurc...
Angelalign Technology Reshapes Governance Team With New Company Secretary
May 15, 2026
Angelalign Technology Inc., a Hong Kong-listed dental technology company specialising in clear orthodontic aligners and related services, operates in the competitive medical device and oral care market with a focus on China and regional growth. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.